Proactive Investors - Run By Investors For Investors

ANGLE names diagnostic pathology expert Dr Joseph D Khoury as a scientific advisor

The AIM-listed liquid biopsy company pointed out that Khoury has significant experience in the cytological and morphological analysis of cancer cells
Cancer cell
It added that his expertise is therefore highly relevant to ANGLE's continuing development of its ParsortixTM system

ANGLE plc (LON:AGL) (OTCQX:ANPCY) has announced the appointment of Dr Joseph D Khoury as a scientific advisor to the company's established Scientific Advisory Board.

The AIM-listed liquid biopsy company pointed out that Khoury is a recognised expert in diagnostic pathology and has significant experience in the cytological and morphological analysis of cancer cells.

READ: ANGLE acquires remaining stake in US subsidiary from Parsortix inventor

It added that his expertise is therefore highly relevant to ANGLE's continuing development of its ParsortixTM system as the liquid biopsy platform of choice for harvesting and analysing circulating tumour cells and other rare cells from blood as a means of diagnosing and monitoring disease.

The group said Khoury is a tenured Professor of Pathology and Laboratory Medicine at The University of Texas MD Anderson Cancer Center in Houston, Texas and is the Executive Director of the MD Anderson Cancer Network for the Division of Pathology and Laboratory Medicine and the Director of the MD Anderson Institutional Immunohistochemistry Laboratory.

ANGLE founder and chief executive, Andrew Newland, commented: "Our Parsortix system has been shown to enable the efficient harvesting of circulating cancer cells and other rare cells in patient blood.

“Dr Khoury's expertise in interpreting these cells and their relevance to a patient's condition, and potentially their prognosis and treatment, is expected to open up new possibilities for the use of Parsortix system. “

View full AGL profile View Profile

ANGLE PLC Timeline

Related Articles

1550762209_shutterstock_291998651.jpg
February 21 2019
Motif’s lead drug candidate is iclaprim, a next-generation antibiotic for which it was seeking US FDA approval for use in patients with acute bacterial skin and skin structure infections
scientist in lab
February 25 2019
Results from a 62-patient follow-up study are due shortly, while data from a 500-person-strong managed access programme should be available by the end of next year
A doctor's stethoscope and a marijuana plant
February 22 2019
With top-line data from the CONNECT-FX trial on the way, investors are eying the opportunity defined by marijuana-adjacent companies like Zynerba Pharmaceuticals

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use